Providing Market Intelligence for 40 Years

In The News

mHealth Still Missing the Comfort Zone for Chronic Care Patients

A report from digital health analyst Parks Associates indicates 27 percent of those surveyed with a chronic condition want a mobile health device that tracks their condition – yet significant numbers also report that the devices they now have are too complicated to use or don’t work properly.

"Nearly one-half of type I diabetics and one-third of type II diabetics are interested in health monitoring devices such as glucometers, but a steep learning curve and difficult or counterintuitive directions could inhibit their usage of these devices and also prevent them from buying other connected health devices," Harry Wang, the group’s senior director of research, said in a press release accompanying the report. "Device and application manufacturers would benefit from improving the ease-of-use of these devices."

The study points to a continuation of missed opportunities in mHealth for both patients and their caregivers. 

From the article "mHealth Still Missing the Comfort Zone for Chronic Care Patients" by Eric Wicklund.

Previously In The News

Will Apple TV kill the cable box? Not so fast

To go a step further, Apple could embrace over-the-air antennas, whose usage is still on the rise as cable subscriptions sink. (According to Parks Associates, roughly 20 percent of U.S. homes with bro...

Report: Antenna Only Homes Increase to 15 Percent

While we’re certainly no longer in the days where people had a pair of rabbit ears on top of their TV sets, the use of antennas are making a little bit of a comeback according to a recent report from...

Roku Plunges: 3 Reasons to Buy, 4 Reasons to Sell

Last August, Parks Associates reported that Roku controlled 37% of the streaming device market in the U.S., while Amazon, Google, and Apple held shares of 24%, 18%, and 15%, respectively. All three of...

The Simple Reason Why I Won't Buy Roku Inc.

Roku (NASDAQ:ROKU) went public on Sep. 28, its stock surging nearly 70% from its IPO price of $14 per share. The stock hit almost $30 the following day, but subsequently pulled back to the low $20s....